Clinical use of new oral anticoagulant drugs: Dabigatran and rivaroxaban

British Journal of Haematology

Volumn 163, Issue 2, 2013, Pages 160-167

  Baglin, Trevor ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Anticoagulants; Atrial fibrillation; Dabigatran; Rivaroxaban; Venous thromboembolism

Indexed keywords

AMIODARONE; ANTACID AGENT; ANTIFUNGAL AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENYTOIN; PROTHROMBIN COMPLEX; PROTON PUMP INHIBITOR; QUINIDINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAMPICIN; RITONAVIR; RIVAROXABAN; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE; WARFARIN; XIMELAGATRAN;

ANEMIA; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG OVERDOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; THROMBIN TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; RIVAROXABAN; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; DRUG INTERACTIONS; EMBOLISM; FACTOR XA; HEMORRHAGE; HUMANS; MORPHOLINES; STROKE; THIOPHENES;

EID: 84884985467     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12502     Document Type: Review

References (27)

1. Asmis, L.M., Alberio, L., Angelillo-Scherrer, A., Korte, W., Mendez, A., Reber, G., Seifert, B., Stricker, H., Tsakiris, D.A. & Wuillemin, W.A. (2011) Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories. Thrombosis Research, 129, 492-498.
2. Baglin, T., Keeling, D. & Kitchen, S. (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. British Journal of Haematology, 159, 427-429.
3. Baruch, L. & Sherman, O. (2011) Potential inaccuracy of point-of-care INR in dabigatran-treated patients. The Annals of Pharmacotherapy, 45, e40.
4. Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., Lensing, A.W., Misselwitz, F., Prins, M.H., Raskob, G.E., Segers, A., Verhamme, P., Wells, P., Agnelli, G., Bounameaux, H., Cohen, A., Davidson, B.L., Piovella, F. & Schellong, S. (2010) Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine, 363, 2499-2510.
5. Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36, 386-399.
6. Buller, H.R., Prins, M.H., Lensin, A.W., Decousus, H., Jacobson, B.F., Minar, E., Chlumsky, J., Verhamme, P., Wells, P., Agnelli, G., Cohen, A., Berkowitz, S.D., Bounameaux, H., Davidson, B.L., Misselwitz, F., Gallus, A.S., Raskob, G.E., Schellong, S. & Segers, A. (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. New England Journal of Medicine, 366, 1287-1297.
7. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D. & Wallentin, L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139-1151.
8. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 1573-1579.
9. Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.M., Emmerich, J., Marchand-Leroux, C., Lecompte, T. & Samama, C.M. (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 116, 94-102.
10. Gomez-Outes, A., Terleira-Fernandez, A.I., Suarez-Gea, M.L. & Vargas-Castrillon, E. (2012) Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons. British Medical Journal, 344, e3675.
11. Gruber, A., Marzec, U., Buetehorn, U., Hanson, S. & Perzborn, E. (2009) Reversal of the antihaemostatic effects of rivaroxaban by activated factor VII and activated prothrombin complex in primates. Haematologica, 94, 181 Abstract 0449.
12. Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z., Nelson, M.E., Wells, P.S., Gould, M.K., Dentali, F., Crowther, M. & Kahn, S.R. (2012) Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest, 141, e419S-e494S.
13. Lambourne, M.D., Eltringham-Smith, L.J., Gataiance, S., Arnold, D.M., Crowther, M.A. & Sheffield, W.P. (2012) Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. Journal of Thrombosis and Haemostasis, 10, 1830-1840.
14. Lee, A.Y., Rickles, F.R., Julian, J.A., Gent, M., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M. & Levine, M.N. (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology, 23, 2123-2129.
15. Lindahl, T.L., Baghaei, F., Blixter, I.F., Gustafsson, K.M., Stigendal, L., Sten-Linder, M., Strandberg, K. & Hillarp, A. (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thrombosis and Haemostasis, 105, 371-378.
16. Lu, G., DeGuzman, F.R., Hollenbach, S.J., Karbarz, M.J., Abe, K., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P.B., Phillips, D.R. & Sinha, U. (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine, 19, 446-451.
17. Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., Fox, K.A. & Califf, R.M. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365, 883-891.
18. Pragst, I., Zeitler, S.H., Doerr, B., Kaspereit, F.J., Herzog, E., Dickneite, G. & van Ryn, J. (2012) Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. Journal of Thrombosis and Haemostasis, 10, 1841-1848.
19. Samama, M.M., Martinoli, J.L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F. & Perzborn, E. (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thrombosis and Haemostasis, 103, 815-825.
20. Samama, M.M., Contant, G., Spiro, T.E., Perzborn, E., Guinet, C., Gourmelin, Y., Le Flem, L., Rohde, G. & Martinoli, J.L. (2011) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thrombosis and Haemostasis, 107, 379-387.
21. Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H. & Litzenburger, T. (2013) A specific antidote for dabigatran: functional and structural characterization. Blood, 121, 3554-3562.
22. Schulman, S. & Crowther, M.A. (2012) How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood, 119, 3016-3023.
23. Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J. & Goldhaber, S.Z. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine, 361, 2342-2352.
24. Stangier, J. & Feuring, M. (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagulation and Fibrinolysis, 23, 138-143.
25. Wallentin, L., Yusuf, S., Ezekowitz, M.D., Alings, M., Flather, M., Franzosi, M.G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., Pogue, J., Reilly, P.A., Yang, S. & Connolly, S.J. (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet, 376, 975-983.
26. Weitz, J.I., Quinlan, D.J. & Eikelboom, J.W. (2012) Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation, 126, 2428-2432.
27. Zhou, W., Schwarting, S., Illanes, S., Liesz, A., Middelhoff, M., Zorn, M., Bendszus, M., Heiland, S., van Ryn, J. & Veltkamp, R. (2011) Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke, 42, 3594-3599.